Compare Amgen, Inc. (AMGN) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Dollar General Corp. — how do they compare? Amgen, Inc. trades at $360.87 (market cap $196.12B), while Dollar General Corp. trades at $125.47 (market cap $26.23B). The key difference: Amgen, Inc. is far larger — about 7.5× Dollar General Corp.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DG | |
|---|---|---|
Market Cap | $196.12B | $26.23B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $156.26 |
52-Week Low | $271.18 | $95.94 |
Enterprise Value | $241.41B | $40.68B |
Dividend Yield | 2.77% | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Dollar General (DG) trades at $118.92, up 2.76% today, with a neutral technical signal and bearish moving averages. The stock shows strong valuation metrics with a P/E of 16.82 and P/S of 0.61, supported by three consecutive quarterly earnings beats. Revenue grew to $40.61B in 2025, though net margins compressed to 2.77%. Positive news highlights margin expansion and back-to-school initiatives, while cash flow improved to $395M net.
Outlook remains cautiously optimistic with a $128.45 consensus price target implying 8% upside. Risks include margin pressure from inflation and competitive threats. Analyst consensus is 52% Buy, but weak consumer sentiment and technical resistance near $120 may limit near-term gains. Debt reduction trends and dividend coverage provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
